Predicting Diabetic Kidney Disease & Changing Lives
PromarkerD - the prognostic test that can predict the onset of diabetic kidney disease and kidney function decline up to 4 years in advance for patients with type 2 diabetes (T2D).
DKD develops in 1 in 3 people with T2D and is the leading cause of end-stage renal disease (ESRD).
Using a simple biomarker-based blood test, the risk of a patient developing DKD can be predicted. Through this next-generation proactive approach DKD progression can be identified, managed, and slowed, diverting the patient journey away from expensive kidney-replacement therapies.
In peer-reviewed clinical studies PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease. Patients predicted by PromarkerD to be at high-risk of chronic kidney disease were 13.5 times more likely to develop DKD than low-risk patients.
DKD is the leading cause of chronic and end-stage kidney disease worldwide. Most people with DKD do not have symptoms. PromarkerD is designed as a synergistic modality in the T2D/DKD treatment continuum of care landscape. To access a new standard in patient care for diabetic kidney disease visit https://promarkerd.com/
Brands: The PromarkerD ELISA kit is designed as a synergistic modality in the T2D/DKD treatment continuum of care landscape. Test available as an immunoassay kit and immunoassay LDT.